Smoldering multiple myeloma (SMM) — an early, asymptomatic precursor of multiple myeloma — often exhibits similar genetic alterations as the full-blown disease, suggesting that patients could benefit from prompt treatment instead of waiting for symptoms to develop, research shows. The findings are paving the way for tests designed to identify patients…
Inserting data from genetically similar patients into a machine-learning algorithm may help predict which multiple myeloma patients will benefit from Velcade (bortezomib) or Revlimid (lenalidomide) treatment, a study shows. Those findings were reported in the study, “Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects,” published…
A triple combination treatment — dendritic cell vaccination plus Revlimid (lenalidomide) and an anti-PD-1 checkpoint inhibitor — led to stronger anti-tumor immune responses against myeloma in mice, a study reports. The study, “Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a…
Get regular updates to your inbox.